Department of Cardiology, University Hospital of Zürich, Rämistrasse 100, Zürich 8091, Switzerland.
Department of Internal Medicine, Triemli Hospital Zürich, Birmensdorferstrasse 497, 8063 Zürich, Switzerland.
Heart Fail Clin. 2021 Oct;17(4):697-708. doi: 10.1016/j.hfc.2021.05.013.
Heart transplantation (HTx) is the treatment of choice in patients with late-stage advanced heart failure (Advanced HF). Survival rates 1, 5, and 10 years after transplantation are 87%, 77%, and 57%, respectively, and the average life expectancy is 9.16 years. However, because of the donor organ shortage, waiting times often exceed life expectancy, resulting in a waiting list mortality of around 20%. This review aims to provide an overview of current standard, recent advances, and future developments in the treatment of Advanced HF with a focus on long-term mechanical circulatory support and HTx.
心脏移植（HTx）是晚期心力衰竭（Advanced HF）患者的首选治疗方法。移植后 1、5 和 10 年的生存率分别为 87%、77%和 57%，平均预期寿命为 9.16 年。然而，由于供体器官短缺，等待时间往往超过预期寿命，导致等待名单上的死亡率约为 20%。本综述旨在提供当前标准、近期进展和未来发展的概述，重点关注长期机械循环支持和 HTx 在 Advanced HF 中的治疗。
